Loading...
•
Sep 30, 2023
Revance Q3 2023 Earnings Report
Revance's Q3 2023 financial results were reported, highlighting significant revenue growth and strategic initiatives.
Key Takeaways
Revance reported a near doubling of total revenue to $56.8 million compared to the same period last year, driven by the commercialization of DAXXIFY and sales growth of the RHA Collection. The company is focusing on capital allocation priorities and expects to reach positive Adjusted EBITDA in 2025.
Total revenue increased to $56.8 million, nearly double the revenue from the same quarter last year.
DAXXIFY revenue reached $22.0 million for the quarter and $71.0 million in its first full year post-approval.
RHA Collection revenue grew to $32.1 million, marking a 23.2% year-over-year increase.
DAXXIFY was approved for cervical dystonia, with the PrevU program treating over 150 patients.
Forward Guidance
Revance anticipates GAAP operating expenses between $545 million and $585 million and non-GAAP operating expenses between $315 million and $335 million for 2023. The company expects to reach positive Adjusted EBITDA in 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...